# Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT06578624** · PHASE1,PHASE2 · RECRUITING · sponsor: **Lamassu Bio Inc** · enrollment: 70 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SA53-OS (phase 1)
- **DRUG:** SA53-OS (phase 2)

## Key facts

- **NCT ID:** NCT06578624
- **Lead sponsor:** Lamassu Bio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-03
- **Final completion:** 2028-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578624, "Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06578624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*